ReviewMedical molecular morphology2012
Overexpression of p53 protein in human tumors.
Review in Medical molecular morphology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Molecular and immunohistochemical markers in appendiceal mucinous neoplasms: A systematic review and comparative analysis with ovarian mucinous neoplasms and colorectal adenocarcinoma.Histology and histopathology · 2025Pooled it
- p53 expression in patients with ulcerative colitis - associated with dysplasia and carcinoma: a systematic meta-analysis.BMC gastroenterology · 2017Pooled it
- pERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer: a translational subgroup analysis from AIO-PK0104.BMC cancer · 2014Trial
- An integrative machine learning and structure-driven drug repositioning strategy for human IRAK4-targeted cancer therapy.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Characterization of p53 p.T253I as a pathogenic mutation underlying Li-Fraumeni Syndrome.PloS one · 2025Article
- Does immunohistochemical staining of P53, Ki 67 and cyclin A accurately predict Wilms tumor recurrence and survival?Arab journal of urology · 2022Article
- Developmental Acquisition ofGenes · 2021Review
- Promising New Tools for Targeting p53 Mutant Cancers: Humoral and Cell-Based Immunotherapies.Frontiers in immunology · 2021Review
- Functions of p53 in pluripotent stem cells.Protein & cell · 2020Review
- Association ofBiomedical reports · 2015Article
- Article
- Dietary diindolylmethane suppresses inflammation-driven lung squamous cell carcinoma in mice.Cancer prevention research (Philadelphia, Pa.) · 2015Article
- Expression and functions of galectin-7 in ovarian cancer.Oncotarget · 2014Article
- Translational research in pancreatic ductal adenocarcinoma: current evidence and future concepts.World journal of gastroenterology · 2014Review
- Association of p53 expression with prognosis in patients with esophageal squamous cell carcinoma.International journal of clinical and experimental pathology · 2014Article
- The protein p17 signaling pathways in cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2013Article
- Pulmonary oxidative stress, inflammation and cancer: respirable particulate matter, fibrous dusts and ozone as major causes of lung carcinogenesis through reactive oxygen species mechanisms.International journal of environmental research and public health · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
According to the current concept of carcinogenesis, neoplastic transformation consists of multistep accumulations of adverse genetic and epigenetic events. p53 is a transcription factor that regulates cellular response to diverse forms of stress through a complex network which monitors genome integrity and cell homeostasis. Mutant p53 loss-of-function, dominant-negative, and gain-of-function properties have been implicated in the development of a wide variety of human cancers, and it is generally accepted that p53 is a component in biochemical pathways central to human carcinogenesis. Study of p53 has come to the forefront of cancer research, and detection of its abnormalities during the development of tumors may have diagnostic, prognostic, and therapeutic implications. In this review, we focus on recent research on overexpression of mutant p53 in human cancer, with an emphasis on mutant p53 regulation, gain of function of mutant p53 in transcriptional effects, and the diagnostic, prognostic, and predictive value of p53 overexpression in human cancer.
Indexed as
Identifiers
23001293What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.